Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma

NCT00596804 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00596804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00596804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2004
Completion date
November 30, 2007
Enrollment
39 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, diffuse, lymphoma, diffuse, mixed lymphocytic-histiocytic, non-hodgkin's lymphoma